- Long-Term Efficacy and Safety of Golimumab for Ulcerative Colitis in a Pediatric Inflammatory Bowel Disease Center in Japan
-
Tokita K, Shimizu H, Takeuchi I, Shimizu T, Arai K
- KMID: 2535163
- Pediatr Gastroenterol Hepatol Nutr.
- 2022 Nov;25(6):461-472.
- doi: 10.5223/pghn.2022.25.6.461
Purpose: Golimumab (GLM) is an anti-tumor necrosis factor (TNF)-α antibody preparation known to be less immunogenic than infliximab (IFX) or adalimumab. Few reports on GLM in pediatric patients with ulcerative... -
- CITED
-
- Close
- SHARE
-
- Close
